Materias dentro de su búsqueda.
Mostrando 2,661 - 2,680 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 1.37s Limitar resultados
  1. 2661
    por Parise, Carol A., Caggiano, Vincent
    Publicado 2015
    “…Background. The eight ER/PR/HER2 breast cancer subtypes vary widely in demographic and clinicopathologic characteristics and survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
  2. 2662
    “…While heterozygous Her2(+/-) mice appear to develop in a similar manner to wild type mice (Her2(-/-)), it has proven difficult to generate homozygous Her2(+/+) mice, potentially due to embryonic lethality. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene
  3. 2663
    “…OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients initiating first-line ET monotherapy or CT. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
  4. 2664
    por Varga, Zsuzsanna, Noske, Aurelia
    Publicado 2015
    “…The high rate of equivocal cases (4.1%) did not contribute to increase in overall HER2-positivity, but resulted in delay in definitive HER2-status.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
  5. 2665
    “…The formation of HER2 homodimers plays an important role in breast cancer aggressiveness and progression; however, little is known about its localization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy
  6. 2666
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
  7. 2667
    “…Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
  8. 2668
    por Rennhack, Jonathan, Andrechek, Eran
    Publicado 2015
    “…These findings were found to be conserved in human HER2 positive patients. Patients with high E2F1 activity were shown to have worse outcomes such as relapse free survival and distant metastasis free survival. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients
  9. 2669
    “…All the six patients with a HER2-positive PT had at least one HER2-negative DTC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer
  10. 2670
    “…A Ventana BenchMark ULTRA (Roche Diagnostics) with anti‐HER‐2/neu (4B5) rabbit monoclonal primary antibody and INFORM HER2/neu Dual ISH DNA Probe Cocktail was used for the assays. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
  11. 2671
    “…Co-expression of HER3(V855A) and wild-type HER2 enhances ligand-induced transformation of murine and human cell lines, while HER-targeted inhibitors potently suppress mutant HER3 activity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
  12. 2672
    “…Depletion of HER2 by siRNA sensitized HER2-positive breast cancer cells to irradiation by decreasing STAT3 activity and survivin, a STAT3 target gene, expression in HER2-positive breast cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers
  13. 2673
    “…Mice bearing intraperitoneal human ovarian tumor xenografts demonstrated increased tumor accumulation of Cy5.5 fluorescently labeled siRNA and 70% target gene suppression after treatment with HER2 antibody-directed siRNA nanocarriers. Detection of the expected mRNA cleavage product by 5′ RLM-RACE assay confirmed that suppression occurs via the expected RNAi pathway. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
  14. 2674
    “…The distributions of luminal, luminal‐HER2, HER2 and TN subtypes were 73.2%, 9.8%, 13.4%, and 3.6%, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CD8(+) tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ
  15. 2675
    “…Treatment of HER2+ breast cancer with trastuzumab is effective and combination anti-HER2 therapies have demonstrated benefit over monotherapy in the neoadjuvant and metastatic settings. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells
  16. 2676
    “…This combination may represent a valid therapeutic option in the neoadjuvant therapy for HER2-positive locally advanced BC.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
  17. 2677
    “…BACKGROUND: HER2/neu-positive breast cancer cells have recently been shown to use a unique Warburg-like metabolism for survival and aggressive behavior. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
  18. 2678
    “…BACKGROUND: Her2/neu is an oncogene that plays an important role in the pathogenesis of many cancer types. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
  19. 2679
    “…PURPOSE: This study evaluated the association of serum HER2 (sHER2) levels at diagnosis with clinicopathologic parameters and disease free survival (DFS) in operable breast cancer patients according to intrinsic subtype. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients
  20. 2680
    “…In addition, ATG9A indirectly promoted c-Cbl recruitment to Her2 on T1112, a known c-Cbl docking site, leading to increased K63 Her2 polyubiquitination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation
Herramientas de búsqueda: RSS